Dec 9, 2021

Geneva, SWITZERLAND GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data on its lead pipeline asset, the PI3Kδ inhibitor IOA-244, showing no dose-limiting toxicity and a reduction in T regulatory (Treg) cells. The data is being presented as a poster at the European Society of Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) taking place on December 8–11, 2021 as a virtual meeting. The data demonstrates there were no dose-limiting toxicities in patients with solid tumors treated with IOA-244, including patients who were treated for up to 1 year duration. The PK profile of IOA-244 showed low inter- and intra-patient variability with no clinically relevant reactive metabolites detected. Mesothelioma, cutaneous and uveal melanoma – tumor types being treated with IOA-244 - are known to have a high burden of T regulatory cells. IOA-244 administration was associated with a reduction in Treg counts in the peripheral blood of patients with uveal melanoma, as measured using cytometry by time of flight (CyTOF). These data strengthen the rationale for treating patients with IOA-244 and expanding the DIONE-01 study, a two-part, first-in-human dose study evaluating IOA-244 in solid tumors and hematologic malignancies. The poster at ESMO-IO presents data from the first part (Part A) of the DIONE-01 study and is entitled “First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma” (P139). The e-poster presentation is available on the ESMO-IO virtual meeting platform and iOnctura’s website . IOA-244 is a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor with an unprecedented preclinical and clinical profile, currently being investigated in Part B of the DIONE-01 trial. Contacts